PDGFRB and hepatocellular carcinoma: Among 23 TKIs approved by FDA, only sorafenib, a multi-kinase inhibitor with activity against Raf and several other RTKs, including VEGFR2, PDGFR, FLT3 and c-KIT, has shown survival benefits for advanced HCC patients1,2,14.